These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24332488)

  • 1. Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.
    Ernst JT; Liu M; Zuccola H; Neubert T; Beaumont K; Turnbull A; Kallel A; Vought B; Stamos D
    Bioorg Med Chem Lett; 2014 Jan; 24(1):204-8. PubMed ID: 24332488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.
    Ernst JT; Neubert T; Liu M; Sperry S; Zuccola H; Turnbull A; Fleck B; Kargo W; Woody L; Chiang P; Tran D; Chen W; Snyder P; Alcacio T; Nezami A; Reynolds J; Alvi K; Goulet L; Stamos D
    J Med Chem; 2014 Apr; 57(8):3382-400. PubMed ID: 24673104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Inhibition of the Hsp90α Isoform.
    Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
    Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of heat shock protein 90 isoforms in small cell lung cancer.
    Lee JH; Kang KW; Kim JE; Hwang SW; Park JH; Kim SH; Ji JH; Kim TG; Nam HY; Roh MS; Lee EH; Park MI; Kim MS; Lee HW
    Int J Clin Exp Pathol; 2015; 8(8):9487-93. PubMed ID: 26464709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
    Mak OW; Chand R; Reynisson J; Leung IKH
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosynthesis and preclinical evaluation of [
    Cools R; Vermeulen K; Narykina V; Leitao RCF; Bormans G
    EJNMMI Radiopharm Chem; 2023 Jan; 8(1):2. PubMed ID: 36715827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
    Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
    FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
    Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
    ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities.
    Dernovšek J; Tomašič T
    Pharmacol Ther; 2023 May; 245():108396. PubMed ID: 37001734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosolic Hsp90α and its mitochondrial isoform Trap1 are differentially required in a breast cancer model.
    Vartholomaiou E; Madon-Simon M; Hagmann S; Mühlebach G; Wurst W; Floss T; Picard D
    Oncotarget; 2017 Mar; 8(11):17428-17442. PubMed ID: 28407697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
    Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
    J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
    Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
    Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Grp94 inhibitor.
    Duerfeldt AS; Peterson LB; Maynard JC; Ng CL; Eletto D; Ostrovsky O; Shinogle HE; Moore DS; Argon Y; Nicchitta CV; Blagg BS
    J Am Chem Soc; 2012 Jun; 134(23):9796-804. PubMed ID: 22642269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of HSP90 isoforms and their correlations with clinicopathologic factors in patients with colorectal cancer.
    Kim K; Lee HW; Lee EH; Park MI; Lee JS; Kim MS; Kim K; Roh MS; Pak MG; Oh JE; Kim KM; Lee JW; Kim TG; Nam HY
    Int J Clin Exp Pathol; 2019; 12(3):978-986. PubMed ID: 31933908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAP1: a viable therapeutic target for future cancer treatments?
    Lettini G; Maddalena F; Sisinni L; Condelli V; Matassa DS; Costi MP; Simoni D; Esposito F; Landriscina M
    Expert Opin Ther Targets; 2017 Aug; 21(8):805-815. PubMed ID: 28664757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells.
    Ghosh S; Shinogle HE; Garg G; Vielhauer GA; Holzbeierlein JM; Dobrowsky RT; Blagg BS
    ACS Chem Biol; 2015 Feb; 10(2):577-90. PubMed ID: 25402753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.
    Liu S; Street TO
    Protein Sci; 2016 Dec; 25(12):2209-2215. PubMed ID: 27667530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
    Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
    Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease.
    Khalid S; Paul S
    Med Hypotheses; 2014 Jul; 83(1):39-46. PubMed ID: 24785461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the site 2 pocket of Grp94 with KUNG65 benzamide derivatives.
    Pugh K; Xu H; Blagg BSJ
    Bioorg Med Chem Lett; 2024 Oct; 111():129893. PubMed ID: 39043265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.